Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Lantus er større end risiciene til behandling af diabetes mellitus hos voksne, unge og børn over seks år, hvor der kræves behandling med insulin.
The Committee for Medicinal Products for Human Use (CHMP) decided that Lantus’ s benefits are greater than its risks for the treatment of adults, adolescents and children of six years or above with diabetes mellitus, where treatment with insulin is required.